<DOC>
	<DOCNO>NCT01894165</DOCNO>
	<brief_summary>Phase 1 single dose study ALXN1101 healthy volunteer .</brief_summary>
	<brief_title>Phase 1 Single Dose Study ALXN1101 Healthy Volunteers</brief_title>
	<detailed_description>This first-in-human ( FIH ) , randomize , blind , placebo-controlled , single-dose , sequential-cohort , dose-escalation study evaluate safety , tolerability , pharmacokinetics ( PK ) single dose ALXN1101 healthy adult subject .</detailed_description>
	<mesh_term>Metal Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Key 1 . Male female subject ≥ 18 ≤ 60 year age weight ≥ 55 kg ≤ 100 kg 2 . Willing able give write informed consent 3 . Female subject child bear potential must negative serum pregnancy test must practice approved contraceptive regimen duration study 4 . Male subject must practice acceptable barrier method contraception Key 1 . Pregnant nursing female subject 2 . QTcF &gt; 450 msec male &gt; 470 msec female , family history Long QT Syndrome . 3 . CrCl &lt; 80 mL/min 4 . CBC acceptable range ; SGOT SGPT ULN 5 . HIV , Hepatitis B Hepatitis C virus infection 6 . Other active systemic infection malignancy 7 . Investigational drug study within 60 day 8 . Major surgery within prior 90 day 9 . History illicit drug use chronic alcohol dependence within 2 year prior study 10 . Positive urine drug toxicology screen serum alcohol test 11 . Alcohol consumption within 48 hour prior study drug administration 12 . Recently donate lose ≥ 499 mL blood 13 . Recent hormone replacement therapy use prescription medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>molybdenum cofactor deficiency ( MoCD )</keyword>
	<keyword>deficiency activity molybdenum-dependent enzyme</keyword>
</DOC>